
Dr Morgans on HRQOL Outcomes With Darolutamide Plus ADT in mHSPC
"Importantly, this combination shows both efficacy in terms of cancer control, but also this maintenance or improvement in QOL that is important for patients. When we get to that ultralow or low PSA, we’re getting better cancer control and probably …